People · Operator
Named in public records as an officer, director or promoter · active 2018–2019 · Pharma, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Celsius Therapeutics, Inc. | — | Pharma | Series C | $48.0M | $1.7B | 2018 |
| HOOKIPA Pharma Inc. | — | Pharmaceuticals | Series B | $37.4M | $1.3B | 2019 |
Christoph Lengauer at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Christoph Lengauer on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Kelly | 1 | 11 |
| Alexis Borisy | 1 | 6 |
| Graziano Seghezzi | 1 | 3 |
| Julie O'Neill | 1 | 2 |
| Joern Aldag | 1 | 1 |
| Paul-Henri Lambert | 1 | 1 |
| Jan Van De Winkel | 1 | 1 |
| Reinhard Kandera | 1 | 1 |
| Sander Van Deventer | 1 | 1 |
| Michael Boretti | 1 | 1 |
| Tariq Kassum | 1 | 1 |
| Colleen DeSimone | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.